Castle Biosciences to Release Third Quarter 2023 Financial Results and Host Conference Call on Thursday, Nov. 2
19 Oktober 2023 - 1:00PM
Business Wire
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, today
announced that it will release its financial results for the third
quarter and nine months ended Sept. 30, 2023, after the close of
market on Thursday, Nov. 2, 2023.
Company management will host a conference call and webcast to
discuss its financial results at 4:30 p.m. Eastern time on the same
day.
Conference Call and Webcast Details
A live webcast of the conference call can be accessed here:
https://events.q4inc.com/attendee/479909909, or via the webcast
link on the Investor Relations page of the Company’s website:
https://ir.castlebiosciences.com/overview/default.aspx. Please
access the webcast at least 10 minutes before the conference call
start time. A replay of the webcast will be available following the
conclusion of the conference call.
To access the live conference call via phone, please dial 1 833
470 1428 from the United States, at least 10 minutes prior to the
start of the call, using the access code 925738. International
dial-in numbers are available here:
https://www.netroadshow.com/events/global-numbers?confId=56585;
please use the same access code above to join the call.
There will be a brief Question and Answer session following
management commentary.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics
company improving health through innovative tests that guide
patient care. The Company aims to transform disease management by
keeping people first: patients, clinicians, employees and
investors.
Castle’s current portfolio consists of tests for skin cancers,
uveal melanoma, Barrett’s esophagus and mental health conditions.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to predict systemic therapy
response in patients with moderate-to-severe psoriasis, atopic
dermatitis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq,
TissueCypher and IDgenetix are trademarks of Castle Biosciences,
Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231019193574/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
Von Mai 2023 bis Mai 2024